Annapoorna Kini
Annapoorna Kini, M.D., is an American cardiologist and a Professor of Cardiology at Mount Sinai School of Medicine in New York City.
Dr. Kini performs over 1,000 coronary interventions annually (the highest number performed by a female interventionalist in the United States and the second highest overall volume in the US) with an extremely low complication rate of less than 0.3 percent. From 2011-2013, Dr. Kini achieved the highest rating of two stars for performing angioplasty with percutaneous intervention with one of the lowest documented rate of complications in New York State Department of Health's PCI Report for that time period. In 2011, an official annual report from The Department of Health recognized Dr. Kini as the safest operator among 350 other physicians in the State of New York Her low complication rate earned her a 2-star rating in the 2012, NY State Annual Department of Health Report; which is the state's highest distinction for safety and clinical outcomes. As Director of the Cardiac Cathertization Laboratory at the prestigious Mount Sinai Hospital in New York, Dr. Kini is responsible for the day-to-day smooth functioning of their high volume catheterization laboratory, which performs more than 15,000 total procedures including 5200 interventions annually. Her safety record and patient outcomes along with her supervision of her Mount Sinai colleagues and staff also garnered Mount Sinai Medical Center's Cardiac Catheterization the prestigious 2-star rating,as well. This distinction from the New York State Department of Health, which came in 2015 marked the 17th consecutive year the Mount Sinai Heart Cardiac Catheterization Laboratoryor its physicians were awarded this prestigious two-star rating for its coronary interventions overall and in non-emergency cases.
Biography
Dr. Annapoorna Kini serves as a Professor of Medicine, Director of Cardiac Catheterization Laboratory, Director of Interventional Structural Heart Disease Program, and Director of Interventional Cardiology Fellowship at The Mount Sinai Medical Center. Dr. Kini is an international leader in the field of percutaneous coronary intervention and heart valve therapy. In 2016, Dr. Kini's contributions to science and medicine led the Mount Sinai Hospital's leadership bestowed upon her the prestigious Zena and Michael A. Wiener Medicine Professorship.
In collaboration with Dr. Sharma, she started the Live Symposium of Complex Coronary and Vascualr Cases in 1998 and has been receiving an astounding success every year. Her achievements are not only limited to serving as the Director of the Annual Live Symposium of Complex Coronary & Vascular Cases at The Mount Sinai Medical Center, one of the most attended and respected meetings in the field of interventional cardiology in the country, but as also being the Director of monthly web conferences on Live Complex Coronary Intervention Cases hosted by the prestigious www.cardiosource.org with a worldwide audience of several thousand physicians across 131 countries garnering over 7000 page views.
She has an extensive experience with the techniques of mitral and aortic balloon valvuloplasty, and has been among the first interventional cardiologists in the country to use transcutaneous aortic valve implantation procedure in the treatment of unoperable patients with critical aortic stenosis.
Dr. Kini is widely published on various topics of Interventional Cardiology and has authored numerous book chapters in the field of Acute Coronary Syndromes and cornoray interventions. She serves as the site Principal Investigator for numerous multi-center trials including sponsored trials by the National Institutes of Health (NIH). She also maintains a large interventional database of more than 50,000 heart patients, which helps in analysis and publications of short and long-termoutcomes of all types of coronary interventions.
She is co-author (with Dr. Samin K. Sharma) of Coronary artherectomy: Contemporary concepts in cardiology and (with Dr. Valentin Fuster) of Definitions of acute coronary syndromes in Hurst's The Heart.[1]
Education
Kini graduated from India's Vivekananda College in 1984. She received her MBBS from Kasturba Medical College in 1991 receiving 3 honors and gold medals, completing residencies at the University of Wales College of Medicine (in 1996). After receiving training in England, she became a member of the Royal College of Physicians of London. She completed three fellowships at Mount Sinai Medical Center – in 1997, 2001, and 2002, respectively.[2]
Personal life
Annapoorna Kini currently resides in New York and is married with two children. One is a senior at Columbia University, and will become a master investment banker/bhangra dancer. Dr. Kini has a passion for yoga/meditation and running, one she shares with colleagues, staff, and patients at Mount Sinai hosting yoga events and an annual fun run, in which she engages health care professionals in their personal well-being.
Awards and recognition
- 2016-Zena and Michael A. Werner Professor of Medicine
- 2016-"Two-star rating" New York Department of Health Annual Report 2013 for safety outcomes
- 2015-"Two-star rating" New York Department of Health Annual Report 2012 for safety outcomes
- 2014-"Physician of the Year" by the Department of Nursing at Mount Sinai Hospital
- 2011- “Dean's Award for Excellence in ClinicalMedicine”. Mount Sinai Hospital
- 2011-“Rock Star of Science” award from AHA at Grand Hyatt, New York
- 2011- Dean's Award for Excellence in Clinical Medicine at The Mount Sinai Medical Center.
- 1999- Young Investigator Award of American Association of Cardiology of Indian Origin (AAICO).
- 1990- Gold medal for best outgoing student in the Final MBBS ( Mangalore University).
- 1989- Gold medal (First Place) in Internal Medicine (Ophthalmology and Anatomy) from Mangalore University.
Grants and trials
- Chronometric Observations of Lipid CoreContaining Plaques of Interest in Native Coronary Arteries Registry: COLORRegistry. Sponsored by Infra ReDx Inc.
- A randomized, double-blind, triple-dummy trialto compare the efficacy of otamixaban with Unfractionated Heparin +eptifibatide, in patients with Unstable angina/Non ST segment ElevationMyocardial infarction scheduled to undergo and early invasive strategy.EKG-Glove. Sponsored by Ineed MD.
- YELLOW Trial: The study will assess theregression of yellow plaque content of the lipid pool after aggressive lipidtherapy by utilizing NIR spectroscopy. Intense statin therapy usingRosuvastatin 10–40 mg will be compared to the standard statin therapy.Sponsored by MSSM.
- Expert CTO Trial: A prospective, multi-center, single-arm study toestablish the safety and efficacy of XIENCE V Everolimus Eluting CoronaryStent, XIENCE nano Everolimus Eluting Coronary Stent, HI-TORQUE PROGRESSCoronary Guide Wires, HI-TORQUE PILOT Coronary Guide Wires and MINI-TREKCoronary Dilatation Catheter in patients undergoing elective percutaneousrevascularization of native chronic total coronary occlusions. Sponsored by Abbott Vascular.
- Excel Trail: Evaluationof XIENCE PRIME™ or XIENCE V®versus Coronary Artery Bypass Surgeryfor Effectiveness of Left MainRevascularization. Role: Sponsored by Abbott Vascular.
- CoreValve®U.S. Pivotal Trial (High Risk Surgical Subjects). Sponsored by Medtronic.
- Tryton SB trial: AProspective, Single Blind, Randomized Controlled Study to Evaluate the SafetyAnd Effectiveness of the Tryton Side Branch Stent™ used in Conjunction with aDrug-Eluting Stent Compared to Side Branch Balloon Angioplasty in Conjunctionwith a Drug-Eluting Stent in the Treatment of de novo BifurcationLesions Involving the Main Branch and Side Branch within the Native CoronaryCirculation. Sponsored by Tryton Medical Inc.
- ABSORB 3: Clinical Evaluation of the ABSORB™ Bioresorbable Vascular Scaffold (BVS)in the Treatment of Subjects with de novo Native Coronary ArteryLesions. Sponsored by Abbott Vascular.
Books, Chapters and Invited contributions
- Kim M, KiniA, Fuster V. Definitions of acute coronarysyndromes: Hurst’s The Heart 11th edition; Chapter 48, 1215-1222, todate since 2004.
- Sharma S, Kini A. Coronary atherectomy. Contemporary concepts incardiology, edited by Richard Gorlin, George Dangas, Pavlos Toutouzas, MKonstadoulakis, Kluwer academic publisher Inc.; 463-478, 1999.
- Kini A. Coronary angiography, lesionclassification and severity assessment. Cardiology Clinics 24(2):153-62, 2006.
- Sharma S, Kini A. Coronary bifurcation lesions.Cardiology Clinics 24(2):233-46, 2006.
- Sharma S, Bagga R, Kini A. Debulking approachesprior to stenting in interventional cardiology. Edited by Stephen Ellis and David Holmes, LippincottWilliams & Wilkins 116-124, 2006.
- Sarkar K, Kini A, Sharma S. Treatment ofthrombotic lesions in STEMI: The role of thrombectomy devices. Textbook on newapproaches for STEMI interventions by Sameer Mehta Editor 2008.
- Sharma S, Kini A. Preface. Cardiol Clin.2010.
Publications
Partial list:
- Kini A, Baber U,Kovacic JC. Changes in Plaque Lipid Content After Short-Term, Intensive VersusStandard Statin Therapy: The YELLOW Trial. J Am Coll Cardiol 2013, May 1.
- Kini A,Muntner P, Moreno P, Mann D, Krishnan P, Kim M, Rafael O, Farkouh M, SharmaS. Relation ofHigh-Density Lipoprotein Cholesterol to Mortality After Percutaneous CoronaryInterventions in Patients With Low-Density Lipoprotein <70 mg/dL. Am J Cardiol, 103(3):350-354, 2009.
- Kini A, Rafael O, Sarkar K, Rajdev S, Jakkula M, MaresA, Kaplish D, Krishnan P, Kim M, Sharma S. Changing Outcomes and TreatmentStrategies for Wire Induced Coronary Perforations in the Era of BivalirudinUse. Cathet Cardiovasc Intervent 74(5): 700-7, 2009.
- Kini A, ChenV, Krishnan P, Kim M, Suleman J, Mares A, Moreno P, Sharma S. Bolus-only vs.Bolus + infusion of Glycoprotein Iib/IIIa inhibitors during percutaneouscoronary intervention. Am Heart J 156(3):513-9, 2008.
- Kini A, Kim M,Moreno P, Krishnan P, Ivan O, Sharma S. Comparison of coronary flow reserve andfractional flow reserve in patients with versus without diabetes mellitus andhaving elective percutaneous coronary intervention and abciximab therapy (from the PRECIDT trial). Am J Cardiol 101(6):796-800, 2008.
- Kini A, Moreno P, Steinheimer A, Prattipati M,Suleman J, Kim M, Sharma S. Effectiveness of the Stent Pull-Back Technique forNon-Aorto Ostial Coronary Narrowings. Am J Cardiol 96:1123-1128, 2005.
- Kini A, Lee P, Mitre C, Kim M, Kamran M, DuffyM, Marmur J, Sharma S. Prediction of outcome after percutaneous coronaryintervention for acute coronary syndrome. Am J Med 115:708, 2003.
- Kini A,Lee P, Mitre C, Duffy M, Sharma S. Post-procedure chest painfollowing coronary stenting: Implications on clinical restenosis. J Am CollCardiol 41:33, 2003.
- Kini A,Mitre C, Kamran M, Kim M, Duffy M, Marmur J, Sharma S. Changing trends and predictors of radiographic contrastnephropathy after percutaneous coronary intervention with use of fenoldopam. AmJ Cardiol 89:999, 2002.
- Kini A,Richard M, Suleman J, Perez N, Lee P, Kamran M, Marmur JD, Sharma SK.Effectiveness of tirofiban, eptifibatide, abciximab in minimizing myocardialnecrosis during percutaneous coronary intervention (TEAM pilot study). Am JCardiol 90:526, 2002.
- Kini A,Mitre C, Kim M, Kamran M, Reich D, Sharma S. A protocol for prevention ofradiographic contrast nephropathy during percutaneous coronary intervention:effect of selective dopamine receptor agonist fenoldopam. Cathet CardiovascIntervent 55:159, 2002.
- Kini A,Reich D, Mitre C, Sharma S. A risk stratification scheme for selection of aglycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention basedon clinical and angiographic criteria. Am J Cardiol 88:1287, 2001.
- Kini A,Reich D, Marmur J, Sharma S. Does abciximab limit the CK-MB elevation afterrotational atherectomy of type B2 lesions? Results of the RotaReoPro randomized trial. Am Heart J 142:965, 2001.
- Sharma S, Kini A,Marmur J, Fuster V. Cardio-protective effect of prior beta-blocker therapy inreducing CK-MB elevation after coronary intervention: Benefit is extended toimprovement in intermediate term survival. Circulation 102:166, 2000.
- Kini A,Marmur J, Dangas G, Santiago M, Choudhary S, Sharma S. Angiographic patterns ofin-stent restenosis and implications on subsequent revascularization. CathetCardiovasc Intervent 49:23, 2000.
- Kini A, MarmurJ, Kini S, Dangas G, Wallenstein S,Cocke T, Brown E, Ambrose J, Sharma S. Creatine kinase-MB elevation aftercoronary intervention correlates with diffuse atherosclerosis and low-to-mediumlevel elevation has a benign clinical course: Implication for early dischargeafter coronary intervention. J Am Coll Cardiol 34:663, 1999.
- Kini A, KiniS, Marmur J, Bertea T, Dangas G, Cocke T, Sharma S. Incidence and mechanism ofcreatine kinase-MB enzyme elevation after coronary intervention with differentdevices. Cathet Cardiovasc Intervent 48:123, 1999.
- Kini A, Marmur J, Duvvuri S, Choudhary S, Dangas G, Sharma S. Rotational Atherectomy:Improved procedural outcome with evolution of technique and equipment - Singlecenter results of 1000 patients. Cathet Cardiovasc Intervent 46:305,1999.
References
- ↑ Nash, Ira S.; Fuster, Valentin; O'Rourke, Robert A.; Roberts, Robert W.; King, Spencer Bidwell; Prystowsky, Eric N. (2004). Hurst's the heart. New York City: McGraw-Hill. ISBN 978-0-07-143225-2. OCLC 52720664.
- ↑ Dr. Annapoorna Kini (2010-02-22). "Vitals". Vitals. Retrieved 2010-10-25.
External links
- The Live Symposium of Complex Coronary Cases homepage
- Mount Sinai Hospital homepage
- Mount Sinai School of Medicine